SWM
VRTX icon

SeaCrest Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

SeaCrest Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-459
Closed -$222K – 674
2025
Q4 		$222K Buy
+459
New +$198K 0.02% 559
2025
Q3 		– Sell
-474
Closed -$211K – 679
2025
Q2 		$211K Sell
474
-289
-38% -$133K 0.02% 563
2025
Q1 		$370K Buy
+763
New +$356K 0.04% 413
2020
Q4 		– Sell
-1,361
Closed -$370K – 649
2020
Q3 		$370K Hold
1,361
– – 0.06% 327
2020
Q2 		$395K Buy
1,361
+145
+12% +$39.3K 0.07% 306
2020
Q1 		$289K Buy
+1,216
New +$279K 0.06% 332
2019
Q2 		– Sell
-459
Closed -$84K – 1814
2019
Q1 		$84K Sell
459
-4
-0.9% -$739 0.01% 761
2018
Q4 		$77K Sell
463
-699
-60% -$121K 0.02% 759
2018
Q3 		$224K Sell
1,162
-50
-4% -$8.9K 0.04% 469
2018
Q2 		$206K Sell
1,212
-121
-9% -$18.8K 0.04% 480
2018
Q1 		$217K Buy
1,333
+108
+9% +$17.6K 0.04% 466
2017
Q4 		$184K Buy
+1,225
New +$181K 0.03% 523

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

SeaCrest Wealth Management's VRTX Position: Q1 2026 in Review

SeaCrest Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 459 shares — an estimated $222K sold.

SeaCrest Wealth Management first reported a position in VRTX in Q4 2017 and held it in 12 quarters. The position peaked at $395K in Q2 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • SeaCrest Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SeaCrest Wealth Management sold 459 Vertex Pharmaceuticals shares in Q1 2026, an estimated $222K.
  • SeaCrest Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and held it in 12 quarters.
  • SeaCrest Wealth Management's Vertex Pharmaceuticals position peaked at $395K in Q2 2020.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on SeaCrest Wealth Management's 13F filing for Q1 2026, filed 15 Apr 2026.